CAI (Caris Life Sciences) Other Financing: $108.4 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CAI Caris Life Sciences Inc CAI
11 GF Score
Price $15.53
! 2 Warning Signs
View Full Analysis

What is Caris Life Sciences Other Financing?

Caris Life Sciences CAI -0.89% 11 Other Financing is $108.4 Mil as of Mar. 2026. GuruFocus rates CAI with a GF Score™ of 11/100. The stock has 2 warning signs investors should review.

Caris Life Sciences's Other Financing for the three months ended in Mar. 2026 was $0.9 Mil.

Caris Life Sciences's Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 was $108.4 Mil.

Caris Life Sciences Other Financing Historical Data

* Premium members only.

The historical data trend for Caris Life Sciences's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Caris Life Sciences Other Financing Chart

Caris Life Sciences Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Other Financing
11.41 -0.44 0.47 -12.35

Caris Life Sciences Quarterly Data
Dec22 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 1.33 129.10 -21.07 -0.47 0.86
CAI
11GF Score
Caris Life Sciences Inc CAI
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Caris Life Sciences Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $108.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of $108.4 Mil mean?
Caris Life Sciences (CAI) has a Other Financing of $108.4 Mil as of Mar. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Caris Life Sciences and its competitors.
Is Caris Life Sciences' Other Financing too high?
Caris Life Sciences' current Other Financing is $108.4 Mil. Overall, Caris Life Sciences has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Caris Life Sciences' Other Financing compare to DNTH and MANE?
Caris Life Sciences' Other Financing of $108.4 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Caris Life Sciences and its competitors. Caris Life Sciences's current Other Financing is $108.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Caris Life Sciences stock overvalued right now?
Caris Life Sciences (CAI) has a current Other Financing of $108.4 Mil. The current Other Financing is $108.4 Mil. Caris Life Sciences' overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Caris Life Sciences (CAI), the current Other Financing is $108.4 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Caris Life Sciences Business Description

Other Exchanges CAI:Mexico49J:Germany
Address 750 W. John Carpenter Freeway, Suite 800, Irving, TX, USA, 75039
Caris Life Sciences Inc is a patient-centric, next-generation AI TechBio company. It develop and commercialize solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.
11GF Score

Get the complete analysis for CAI

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$15.53
Price